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Background
Genetic variation in the serotonin transporter gene has
been proposed as a possible explanation for inter-individ-
ual differences in treatment effects of selective serotonin
reuptake inhibitors (SSRIs) in major depression [1-3].
Assessment of these genetic influences is necessary in
order to decide whether genetic testing in psychiatric prac-
tice prior to antidepressant prescription could be useful
[3]. This study evaluates the influence of two polymor-
phisms in the serotonin transporter gene (5-HTTLPR and
STin2) on SSRI treatment outcome in major depression.
Materials and methods
For this study, 50 known non-responders to SSRIs (cases)
and 164 referent patients meeting the DSM-IV criteria for
major depressive disorder and using a SSRI for at least 6
weeks were included in the analyses. Blood samples or
buccal swabs were taken from all participants to deter-
mine the 5-HTTLPR an STin2 genotype. Additional infor-
mation was gathered through interviews. The association
between the serotonin transporter genotype and SSRI
response was assessed by use of logistic regression.
Results
Patients with the 5-HTTLPR s-allele and the STin2 10-
allele appeared to have a non-significantly increased risk
of developing SSRI non-response; Odds Ratio (OR) = 1.51
(95% CI: 0.68–3.33) for 5-HTTLPR and OR = 1.42 (95%
CI: 0.60–3.39) for STin2. After stratification for gender,
the 5-HTTLPR effect appeared to be stronger in female
patients (OR = 3.05, 95% CI: 1.06–8.79) whereas the
STin2 effect tended to be stronger in male patients (OR =
2.21, 95% CI: 0.44–11.09). In addition, an age- depend-
ent effect of 5-HTTLPR and STin2 on treatment outcome
was observed; patients under 42 years old had a non-sig-
nificantly increased risk on SSRI non-response (OR =
2.55, 95% CI 0.75–8.61 for 5-HTTLPR and OR = 2.13,
95% CI 0.54–8.43 for STin2).
Discussion
Our findings indicate that women with the 5-HTTLPR
genotype and men with the STin2 10/10 genotype have a
less favourable response to SSRI treatment in major
depressive disorder. To our knowledge, these findings
have not been reported in studies on the influence of sero-
tonin transporter polymorphisms on treatment effect up
till now. More research is needed, particularly in sub-
groups of depressive patients, before the implementation
of genetic testing in psychiatric practice can be recom-
mended.
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